Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROY: Trastuzumab Deruxtecan in Recurrent Ovarian Cancer
NCT07340164Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Yonsei University. Primary endpoint: Progression Free Survival up to 5 years. Started Feb 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07340164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340164.